Ibere Pharmaceuticals (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on October 22, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with 1 or more businesses (a “Business Combination”).
Company profile
Ticker
IBER
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
981564986
IBER stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
13 Mar 23
25-NSE
Exchange delisting
2 Mar 23
8-K
Ibere Pharmaceuticals Announces Redemption of Public Shares and
15 Feb 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
16 Aug 21
Latest ownership filings
SC 13G
GLAZER CAPITAL, LLC
14 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G
Hudson Bay Capital Management LP
8 Feb 23
SC 13G/A
Hartree Partners, LP
8 Feb 23
SC 13G/A
Magnetar Financial LLC
2 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 22
SC 13G
PIPV Capital LLC
8 Feb 22
SC 13G
Magnetar Financial LLC
14 Jan 22
SC 13G
Hartree Partners, LP
27 Sep 21
SC 13G
CITADEL ADVISORS LLC
12 Mar 21
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.45 k | 4.45 k | 4.45 k | 4.45 k | 4.45 k | 4.45 k |
Cash burn (monthly) | 29.53 k | 56.33 k | 77.87 k | 86.43 k | 96.70 k | 236.95 k |
Cash used (since last report) | 530.95 k | 1.01 mm | 1.40 mm | 1.55 mm | 1.74 mm | 4.26 mm |
Cash remaining | -526.50 k | -1.01 mm | -1.40 mm | -1.55 mm | -1.73 mm | -4.26 mm |
Runway (months of cash) | -17.8 | -17.9 | -17.9 | -17.9 | -17.9 | -18.0 |
Institutional ownership, Q1 2023
25.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 58 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 3.46 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
PIPV Capital | 3.45 mm | $0.00 |
Lynwood Capital Management | 9.80 k | $0.00 |